Kornimate/medical-research-clean huggingface dataset:
registry in chinese young people with sudden cardiac death

Conditions: Sudden Cardiac Death

Summary: the number of sudden cardiac death is up to 540,000 every year in china. inherited cardiovascular disease is a common cause of sudden cardiac death in young people, and diseases often have the characteristics of family aggregation, so it has a huge psychological and economic burden on family members. studying the etiology of sudden cardiac death from the molecular level under the model of precision medicine is helpful for screening patients and their relatives so as to further diagnosis, treatment and management, which has important clinical and social significance.

in this study, sudden cardiac death and high risk of sudden cardiac death in patients younger than 40 years of age are recruited prospectively after informed consent was given. the investigator will collect the baseline clinical characteristics of the patients at enrollment, including comprehensive physical examination, laboratory testing of blood and urine, electrocardiography, 24-hour holter, echocardiography, mri and other examinations if necessary. the specimens retained include blood or oral swabs for all patients, and myocardium for patients receiving autopsy. genetic testing will be performed to identify carried disease genes, genetic risk factors and potential therapy targets.

Eligibility criteria:
inclusion criteria: * patients with sudden cardiac death and sudden unexplained death diagnosed according current practice guidelines. * patients at high risk for sudden cardiac death. (1) family history of sudden cardiac death at a young age; （2）successful resuscitation from cardiac arrest; （3) implantable cardioverter defibrillator implantation after a comprehensive clinical assessment of high risk of sudden cardiac death. exclusion criteria: * patients who refuse to sign the informed consent or decline follow-up. * patients with sudden death due to car accidents, electric shocks, drowning, fighting, carbon monoxide poisoning and other external causes. * patients with sudden death due to other definite causes, such as cerebrovascular accident, severe kidney disease, respiratory disease, neurological disease, etc.
abdominal ultrasonography in urinary tract infection - when and why?

Conditions: Urinary Tract Infections; UTI

Summary: urinary tract infection (uti) in a child may be the first symptom of congenital anomaly of the kidneys and the urinary tract (cakut). thus, imaging diagnostics are warranted in children with first episode of uti. abdominal ultrasonography (usg) is the first line imaging modality in evaluating children with uti. abnormalities suggesting cakut found on usg are an indication for further, more invasive tests. the timing of usg in uti depends on the clinical situation. it always should be performed urgently when serious acute complications of uti are suspected. however, appropriate timing of usg in children responding well to therapy, is a matter of debate. according to animal studies, e. coli produces toxin which dilates the urinary tract. this may result in misleading picture on usg in acute phase of infection. guidelines on uti management in children differ in respect to recommended usg timing. the purpose of the study is to investigate how uti does affect usg results in children and when its effect subsides. methods 150 children up to 3 years of age, with the first episode of uti, will be included in our study. three usg examinations will be performed by single radiologist in every child: 1. in the first day of treatment, 2. two weeks after treatment initiation, 3. four weeks after treatment initiation. age, gender, etiologic factor, c-reactive protein concentration and white blood cells count will be included in statistical analysis. the study is aimed to help clinicians interpret usg findings during uti and make reasonable plans for further imaging diagnostics in children with uti.


Eligibility criteria:
inclusion criteria: - laboratory diagnosis of uti in a child (positive leucocyturia and significant bacteriuria) exclusion criteria: * known previous utis * known congenital abnormality of the kidney and the urinary tract (cakut)
estrogen administration for the treatment of nash in postmenopausal women

Conditions: NASH - Nonalcoholic Steatohepatitis

Summary: non-alcoholic fatty liver disease (nafld) is a growing epidemic in the united states. despite this, the treatment options remain limited. preclinical and preliminary clinical data suggest that estrogen deficiency plays an important role in the pathology of steatosis, inflammation and fibrosis in non-alcoholic steatohepatitis (nash), the progressive form of nafld. post-menopausal women are a growing population with particularly high risk of nash due to their lack of estrogen. this study will examine the effect of estradiol on hepatic fibrosis and fat in post-menopausal women with nash.


Eligibility criteria:
inclusion criteria: * postmenopausal women 45-70 years old * nash by biopsy or nafld by imaging within 6 months of screen * hepatitis c antibody and hepatitis b surface antigen negative * negative mammogram within 1 year exclusion criteria: * heavy alcohol use * use of nash pharmacotherapies within 12 months of study entry * known cirrhosis, stage 4 fibrosis on biopsy, or clinical evidence of cirrhosis or portal hypertension on imaging or exam * participation in nash clinical trial within 6 months of study entry * chronic use of corticosteroids, methotrexate, amiodarone, or tamoxifen within 6 months of entry * known diagnosis of chronic liver disease other than nafld or found on biopsy * contraindication to liver biopsy including inr \> 1.5, platelets \< 50,000/ml, ascites, chronic anticoagulation (other than aspirin), biliary obstruction, peritonitis, inability to lie supine for 30 minutes * hgb \< 10.0 g/dl or glomerular filtration rate \< 60 ml/min * contraindications to estrogen therapy * any vaginal bleeding, including spotting, within the last year * active malignancy * severe chronic illness * use of estrogen or progesterone within a year of baseline visit * routine mri exclusion criteria such as the presence of a pacemaker or cerebral aneurysm clip
prevalence and predictors of depression in copd

Conditions: Depression; COPD

Summary: depression adversely affects quality of life in copd patients, associated with higher rate of exacerbations, admissions and mortality. however, local prevalence rate of depression in geriatric copd patients remains unknown. though bode index is superior to fev1 in prediction of depression in copd, it is unclear which domain of bode correlates best with depression. furthermore, with multiple confounding factors, it's ambiguous that whether frequent exacerbation is an 'independent' predictor for depression among copd patients. the objective of this study is i.) to study the local prevalence rate of depression in geriatric copd patients, ii.) to identify risk factors for depression especially looking at the any independent relationship between frequent exacerbations, various domains of bode index and depression.

this study is a multi-centers, cross-sectional study, conducted in kwong wah hospital and wong tai sin hospital, hong kong sar. age and comorbidity-matched copd and control subjects were recruited from clinics. depressive symptoms were measured by a validated chinese version of geriatric depression scale short form (gds - 15 items) with 2 cut-off points. a score of 8 or above was considered significant depressive symptoms while the cut off score of 5 or above was for patients with mild depressive symptoms. prevalence rates of depressive symptoms were measured in both copd and control groups. predictors for depression (gds = or\> 8) were determined using univariate and multivariate analysis.

Eligibility criteria:
inclusion criteria: * aged 60 or above, * with stable copd suggested clinically and * post-bronchodilator spirometry fev1/fvc ratio \<0.7. exclusion criteria: * patients were excluded if they had co-existing pulmonary diseases like active pulmonary tuberculosis, interstitial lung diseases etc; * if they were too demented or physically incapacitated to participate e.g wheelchair-bound for bedbound.
breast cancer screening via computer v. phone

Conditions: Breast Cancer Screening

Summary: the purpose of this study is to compare mammography adherence among women receiving tailored, interactive mammography interventions via dvd and telephone counseling to usual care.

efficacy study - we will use stratified block randomization based on race to ensure that the treatment groups maintain comparable race composition. participants will be randomly assigned to one of the intervention groups or to usual care. intervention group 1 will receive, by mail, a dvd version of the interactive computer program; based on responses to its queries, the program will supply immediate feedback to promote mammography. intervention group 2 will receive a telephone version of the tailored intervention delivered by a counselor stationed at a computer. the counselor will use questions from the interactive program and deliver messages the program generates in response to each woman's answers. a third group will receive usual care. all women will be asked to participate in 6-month and 21-month follow-up telephone interviews querying stage of mammography adherence and beliefs.

Eligibility criteria:
inclusion criteria: * • must have been a member of their hmo/insurance plan for at least 15 months with records indicating no mammogram (screening or diagnostic) in that 15-month period * current member of the plan at time of study enrollment * no history of breast cancer diagnosis * complete telephone number and mailing address exclusion criteria: * • any claim submitted for a mammogram (screening or diagnostic) in the last 15 months within the hmo/insurance plan or an outside source * previous breast cancer diagnosis * incomplete telephone number or mailing address

Keywords: breast cancer mammography
a study of mircera (c.e.r.a.) in patients with pre-dialysis chronic renal anemia

Conditions: Anemia

Summary: this single arm, open label, multicenter study will evaluate the safety and change in hemoglobin levels of mircera (c.e.r.a.; methoxy polyethylene glycol-epoetin beta) in patients with chronic renal anemia who are not on dialysis. patients will receive as a recommended starting dose 1.2 micrograms of mircera subcutaneously every 4 weeks. the starting dose is dependent on the patient's weight. dose adjustment may be required due to inadequate or excessive treatment response. the anticipated time on study treatment is 28 weeks.


Eligibility criteria:
inclusion criteria: * adult patients, age \>/=18 years * diagnosis of chronic renal anemia * not on dialysis * hemoglobin concentration \<10 g/dl * no erythropoiesis stimulating agent (esa) therapy during the 3 months before study start * estimated glomerular filtration rate (egfr) \ /=20 ml/min * adequate iron status exclusion criteria: * transfusion of red blood cells during the previous 2 months * poorly controlled hypertension * significant acute or chronic bleeding, e.g. gastrointestinal bleeding * active malignant disease (except non-melanoma skin cancer) * hemolysis * hemoglobinopathies, e.g. sickle-cell disease, thalassemia
pilot study of remote glucose monitoring among pediatric patients with type 1 diabetes

Conditions: Type 1 Diabetes

Summary: this project explores the feasibility and utility of remote glucose monitoring for a cohort of children and adolescents with type 1 diabetes (t1d) cared for at uc davis health (ucdh).


Eligibility criteria:
inclusion criteria: * diagnoses of type 1 diabetes with a duration of greater than or equal to 12 months * use of a continuous glucose monitor (cgm) for greater than or equal to 6 months * intention to continue receiving care at the uc davis health pediatric diabetes clinic. exclusion criteria: * patient's cgm cannot be uploaded to glooko
subjects with open-angle glaucoma, pseudoexfoliative glaucoma, or ocular hypertension naïve to medical and surgical therapy, treated with two trabecular micro-bypass stents (istent inject) or travoprost

Conditions: Open-angle Glaucoma

Summary: evaluation of the intraocular pressure (iop) lowering effect of two istent inject devices versus medical therapy in eyes of subjects with primary open-angle glaucoma, pseudoexfoliative glaucoma, or ocular hypertension naïve to medical and surgical therapy.

evaluation of the intraocular pressure (iop) lowering effect of two istent inject devices versus medical therapy in eyes of subjects with primary open-angle glaucoma, pseudoexfoliative glaucoma, or ocular hypertension naïve to medical and surgical therapy.

Eligibility criteria:
inclusion criteria: * phakic study eye * iop ≥ 21 mmhg and ≤ 40 mmhg at the screening visit (subjects with oht require a second screening iop measurement exclusion criteria: * aphakic or pseudophakic eyes (ac-iols or pc-iols) * previous usage of topical prostaglandin analogues or prior medical therapy for glaucoma

Keywords: open angle glaucoma poag ocular hypertension pseudoexfoliative glaucoma naïve to treatment
sertraline and naltrexone for alcohol dependence

Conditions: Alcoholism

Summary: this study is a double-blind, placebo-controlled outpatient trial to improve, through the addition of sertraline (zoloft), the abstinence and relapse rates in alcohol- dependent individuals currently taking naltrexone (revia).


Eligibility criteria:
inclusion criteria: * meets the criteria for alcohol dependence. * abstinent from alcohol for a period of at least 5 days and not greater than 30 days. * able to read english and complete study evaluations. * a stable residence and a telephone to ensure that subjects can be located during the study. exclusion criteria: * currently meets criteria for substance abuse or dependence with the exception of nicotine dependence. * current use of disulfiram (antabuse) or a mao inhibitor. * psychotic or otherwise severely psychiatrically disabled (i.e., depressed, suicidal, current mania). * major depression at the time of assessment. * previous treatment with naltrexone (revia) for alcohol dependence. * significant underlying medical conditions such as cerebral, renal, thyroid, or cardiac disease. * abstinent longer than 30 days prior to admission to program. * hepatocellular disease or elevated bilirubin levels. * females who are pregnant, nursing, or not using a reliable method of birth control.
dosing flexibility study in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: during the run-in period, czp will be administered at 400 mg (2 injections) at wks 0, 2, and 4 and 200 mg with placebo (1 injection placebo, 1 injection czp) at wks 6, 8, 10, 12, 14 and 16. at wk 18 patients will be grouped as responders or non-responders based on results of the acr20 at week 16.

subjects with a stable methotrexate (mtx) dose enter the run-in period in which certolizumab pegol (czp) will be administered at a dose of 400 mg (2 injections) at weeks 0, 2, and 4 and at a dose of 200 mg with placebo (1 injection placebo, 1 injection czp) at weeks 6, 8, 10, 12, 14 and 16. the dose of mtx should be stable for at least 2 months prior to the baseline visit and will remain stable throughout the trial, unless there is a need to reduce the dose for reasons of toxicity. at the week 18 visit, subjects who were acr20 (american college of rheumatology 20% improvement) responders at week 16 will be randomized in a double-blinded way to receive either 400 mg czp given every 4 weeks and placebo given every 4 weeks given as two injections (alternating czp and placebo every two weeks) plus mtx, 200 mg czp and placebo administered every 2 weeks (one injection of each) plus mtx, or placebo administered as two injections every 2 weeks plus mtx. non-responders will be withdrawn from the study.

Eligibility criteria:
inclusion criteria: * patients with established adult rheumatoid arthritis currently on methotrexate for at least 3 months exclusion criteria: * all concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment * previous clinical trials participation and previous biological therapy that could interfere with the results of the present clinical trial

Keywords: rheumatoid arthritis joint disease arthritis certolizumab pegol cimzia
a study on spermatogenesis in male renal transplant recipients receiving valganciclovir (valcyte®) versus untreated matched controls

Conditions: Cytomegalovirus Infections

Summary: this observational study will compare spermatogenesis in male adult renal transplant recipients receiving valganciclovir versus untreated matched controls. data will be collected from each participant for up to 52 weeks post transplant.


Eligibility criteria:
inclusion criteria: * first renal transplant * participant eligible to receive valganciclovir prophylaxis as determined by the treating physician in accordance with the local approved product prescribing information (cohort a only) or the participant is not expected to require any valganciclovir prophylaxis (cohort b only) post-transplant * participant has no history of known infertility * participant is able and willing to provide semen samples * participant agrees to utilize a barrier contraceptive throughout the study or for at least 90 days after cessation of valganciclovir treatment exclusion criteria: * prior ganciclovir or valganciclovir within 3 months of enrollment * organ transplant other than kidney * participant has received an investigational new drug in the 3 months prior to transplant * participant hs received an alkylating agent or other medications known to affect fertility/spermatogenesis * participant is unlikely to be available for follow-up for the entire duration of the study (up to 52 weeks)
gemcitabine and paclitaxel vs gemcitabine alone after folfirinox failure in metastatic pancreatic ductal adenocarcinoma

Conditions: Metastatic Pancreatic Adenocarcinoma

Summary: this study aims to evaluate whether the combination of gemcitabine and paclitaxel allows to improve the overall survival compared to gemcitabine alone, in patients with metastatic pancreatic ductal adenocarcinoma (pdac) after folfirinox failure or intolerance.


Eligibility criteria:
inclusion criteria: * metastatic pancreatic ductal adenocarcinoma with histological or cytological proof * age ≥18 years * at least 1 evaluable lesion according to response evaluation criteria in solid tumors (recist) v1.1 outside any previously irradiated area * failure of first line folfirinox (progressive disease during therapy of within 3 months +/- 15 days) * eastern cooperative oncology group (ecog) performance status ≤2 * life expectancy ≥12 weeks * negative serology (hiv, hepatitis b and c) * adequate organs function * proven post-menopausal status or negative urinary or serum pregnancy test * woman of childbearing potential and male patients must agree to use adequate contraception fo the duration of the trial and up to 6 months after completing treatment * patients affiliated to the social security system * patient must have signed a written informed consent form exclusion criteria: * any other primary tumor or secondary malignancy except basal cell carcinoma of skin or in situ carcinoma of the cervix uteri * known cerebral metastasis * uncontrolled severe infections * patients with kaposi's sarcoma * peripheral neuropathy exceeding grade 2 on common terminology criteria for adverse events (ctcae) v5.0 * previous treatment with taxane and/or gemcitabine (for pancreas cancer only) * patients with known allergy or severe hypersensitivity to any trial drug or drug excipient * patients with any other disease or illness which requires hospitalisation or is incompatible with the trial treatment * patients unable to comply with trial obligations for geographic, social or physical reasons, or who are unable to understand the purpose and procedures of the trial * participation in another clinical trial within 14 days prior to randomization * patients deprived of liberty or under legal protection measures or patients whose willingness to participate in the trial may be unduly influenced

Keywords: metastatic pancreas ductal adenocarcinoma
a study of predictors of the effectiveness of pegylated interferon in a cohort of participants with hepatitis c

Conditions: Hepatitis C, Chronic

Summary: this prospective observational study will investigate predictive values of virological response in pegylated interferon alfa-2a (pegasys)/ribavirin (copegus) treatment-naive participants with chronic hepatitis c. participants will be treated with pegylated interferon alfa-2a and ribavirin as prescribed by the physician. data will be collected for a maximum of 96 weeks.


Eligibility criteria:
inclusion criteria: - diagnosis of chronic hepatitis c infection exclusion criteria: * co-infection with human immunodeficiency virus (hiv) and/or hepatitis b * participants previously treated with pegylated interferon alfa-2a/ribavirin * participation in another clinical study within 30 days prior to study start of ml25544
registry for proton beam radiation therapy

Conditions: Carcinoma

Summary: the goal is to collect information on each patient treated with proton beam radiation therapy.


Eligibility criteria:
inclusion criteria: -any patient receiving proton beam therapy is eligible for enrollment to this registry (regardless of diagnosis, age, other concurrent therapies, etc.) provided s/he consents to participate.
skin surface and intradermal temperature responses to heat stress

Conditions: Hyperthermia

Summary: the purpose of this study is to compare surface and intradermal skin temperature responses to heat stress with and without evaporative and convective cooling.

humans have important thermoregulatory responses aimed at maintaining body temperature within a narrow range. these responses are driven in part by receptors located in the skin that monitor temperature changes and provide feedback to the central nervous system. given that skin temperature can affect the physiological responses to heat stress, it is important to accurately measure skin temperature in response to heat stress with and without evaporative (i.e., sweat) and convective (i.e., air flow) cooling. skin temperature is most often measured on the surface of the skin; however, this temperature can be influenced by other factors such as the local environment. it is unclear how the temperature of the skins surface compares to the temperature within the dermal layer of the skin. the study team will directly compare skin surface and intradermal temperature responses to heat stress and determine whether these responses area altered by evaporative or convective cooling methods. to accomplish this objective, healthy adults will be exposed to ambient heat stress (no higher than 47°c) with and without evaporative (water sprayed on the skin) and convective (electric fan) cooling. thermoregulatory responses, inclusive of skin surface and intradermal temperatures, will be assessed throughout the heat trial.

Eligibility criteria:
inclusion criteria: * free of any significant underlying medical problems based upon a detailed medical history and physical exam. * normal resting electrocardiogram. exclusion criteria: * known heart disease; other chronic medical conditions requiring regular medical therapy including cancer, diabetes, neurological diseases, and uncontrolled hypertension, etc.; as well as serious abnormalities detected on routine screening. * individuals who are pregnant, planning to become pregnant, or breastfeeding. * taking prescribed medications (such as beta blockers and non-dihydropyridine calcium channel blockers) or over-the-counter medications that have known influences on thermoregulatory response. * current smokers, as well as individuals who regularly smoked within the past 3 years.

Keywords: skin temperature intradermal temperature cooling modalities